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Introduction – Acinetobacter baumannii
Bacteria classified to genus Acinetobacter play increas-
ingly important role in pathogenesis of human diseases,
although included to opportunistic pathogen group.
Among members of the genus Acinetobacter baumannii
species is most frequently isolated from humans
[12,113,125]. These organisms are widely distributed in
nature and may be present in soil, water and sewage, also
are found in variety of foodstuffs [39,113,124]. 
Very important place of their occurrence is the hos-
pital environment, especially intensive care units
[10,43,113,132]. Acinetobacters are the second most
commonly isolated nonfermenters in human speci-
mens (Pseudomonas being the first). They are inhabi-
tants of healthy human skin as part of normal flora and
can be readily isolated from moist areas, especially.
Other reservoirs of these organisms may include 
a range of both moist and dry surfaces and equipment
and they can easily survive for many days or weeks,
even in dry condition [10,34,113,115,124]. Occurrence
in the hospital environment, in the patient and staff
favour (favour the spread of diseases in hospital/
amongst other hospitalized patients) hospital-acquired
infections.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 46, No. 3, 2008
pp. 257-267
Multidrug resistant Acinetobacter baumannii – 
the role of AdeABC (RND family) efflux pump 
in resistance to antibiotics
Piotr Wieczorek1, Pawe³ Sacha1, Tomasz Hauschild2, Marcin ¯órawski3, 
Ma³gorzata Krawczyk4, El¿bieta Tryniszewska1
Departments of: 1Microbiological Diagnostics and 3Pharmacology, Medical University of Bialystok, Poland
2Department of Microbiology, Institute of Biology, University of Bialystok, Poland
4Department of Microbiological Diagnostics, University Hospital of Bialystok, Poland
Abstract: Acinetobacter baumannii is an opportunistic pathogen which play the more and more greater role in the patho-
genicity of the human. It is often attached with the hospital environment, in which is able easily to survive for many days
even in adverse conditions. Acinetobacter baumannii is the species responsible for a serious nosocomial infections, espe-
cially in the intensive care units. Option of surviving in natural niches, and in the hospital environment could also be asso-
ciated with the efflux pump mechanisms. Mechanisms of efflux universally appear in all cells (eukaryotic and prokaryotic)
and play the physiological important role. In prokaryote, the main functions are evasion of such naturally produced mole-
cules, removal of metabolic products and toxins. These pumps could also be involved in an early stage of  infection, such
as adhesion to host cells and the colonization. Importantly, they remove commonly used antibiotics from the cell in thera-
py of infections caused by these bacteria. Efflux pumps exemplify a unique phenomenon in drug resistance: a single mech-
anism causing resistance against several different classes of antibiotics. In Acinetobacter baumannii, the AdeABC efflux
pump, a member of the resistance-nodulation-cell division family (RND), has been well characterized. Aminoglicosides,
tetracyclines, erythromycin, chloramphenicol, trimethoprim, fluoroquinolones, some β-lactams, and also recently tigecy-
cline, were found to be substrates for this pump. Drugs, as substrates for the AdeABC pump, can increase the expression of
the AdeABC genes, leading to multidrug resistance (MDR). From this reason, treatment failure and death caused by Acine-
tobacter baumannii infections or underlying diseases are common. Because the AdeABC pump is widespread in Acineto-
bacter baumannii, similarly to other pumps in Gram-negative and Gram-positive bacteria, exists a need of searching a new
therapeutic solutions. Specific efflux inhibitors of pumps (EPIs), including AdeABC inhibitors, could be suppress the activi-
ty of pumps and restore the sensitivity of such important bacteria as Acinetobacter baumannii to commonly used antibiotic.
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Review article
Acinetobacter baumannii is the species most often
responsible for a wide spectrum of nosocomial infec-
tions [68,113,136]. It is infections such as blood-
stream infections, ventilator-associated pneumonia,
urinary tract infections and wound infections [113,124,
129,136]. Sporadic cases peritonitis, endocarditis,
meningitis, osteomyelitis and arthritis have also been
reported [10,113]. In addition, community-acquired
infections have been reported, such as pneumonias [7],
severe wound infections and osteomyelitis caused by
multiresistant Acinetobacter baumannii [15,23]. There
are risk factors such as instrumentation, mechanical
ventilation, surgery, treatment with broad-spectrum
antibiotics, and admission to an intensive care unit for
colonization of patient and environmental cross-infec-
tions [5,10,16,21,140].
Treatment failure and death caused by Acinetobac-
ter baumannii infections or diseases are common [10].
One of the main reasons is that clinical isolates are fre-
quently resistant to many commonly used antimicro-
bial agents (multidrug resistant - MDR) [10,33]. Often
are susceptible only to carbapenems (imipenem,
meropenem), though resistant strains are increasingly
reported, and amikacin, polymyxins, but some may be
susceptible only to polymyxins [29,35,40,43,56,57,74,
106,129,136]. Colonization of the digestive tract inten-
sive care unit patients is an important epidemiologic
reservoir for multi-drug resistant Acinetobacter bau-
mannii infections in hospital outbreaks [22].
In the last few decades Acinetobacter baumannii
has emerged as important opportunistic pathogen,
especially as multiple resistant to the major agents
(MDR) used to treat nosocomial infections
[33,93,136].
Efflux pumps as mechanism of antibiotics
resistance
Bacteria can resist the action of antibiotics through
several mechanisms. The transporting systems are one
of them (in bacteria efflux pumps). Transporters are
present in all organisms (including eukaryotic cells
[130,131]) and could be drive various compounds such
as physiological substrates, non-antibiotic substrates
and antibiotics (different chemical classes) into
(influx) or outside cells (efflux) [11,44,63,65,104,116,
117,120,128]. Bidirectional transporters have also
been found and these can take various roles [62,77,
127,133]. Bacterial efflux pumps that are involved in
clinically relevant resistance to antimicrobial agents,
have also role in bacterial pathogenicity (e.g. in the
colonization and the survival of bacteria in the host)
[14,38,45,64,97].
There are five families of efflux-pump proteins that
are associated with MDR in bacteria: (1) the multidrug
and toxic compound extrusion (MATE) family [13],
(2) the adenosine triphosphate (ATP)-binding cassette
(ABC) superfamily [134], (3) the small multidrug
resistance (SMR) family [90], (4) the major facilitator
superfamily (MFS) [76], and (5) the resistance-nodu-
lation-cell division (RND) family [111]. This classifi-
cation is based on amino acid sequence homology
[96], on the energy source that the pump uses, the
number of components that the pump has (single or
multiple), the number of transmembrane-spanning
regions and the types of substrate that the pump
exports [97]. Drug efflux pumps are found in Gram-
negative and Gram-positive bacteria, but resistance of
this type in Gram-negative bacteria is a more complex
problem due to the molecular architecture of the cell
envelope. Drug resistance in many cases is attributable
to synergy between reduced drug intake (mainly due to
low outer membrane permeability) [85] and active
drug export (via efflux pumps).
The structure of RND-family efflux pumps
Gram-negative bacteria are protected by an outer
membrane, therefore efflux transporters of the RND
family are organized as three-component systems sim-
ilar in various species. The best studied members of
this group are the AcrAB-TolC system of Escherichia
coli [70,71] and the MexAB-OprM system of Pseu-
domonas aeruginosa [99]. These efflux pumps com-
prise the following: a transporter (efflux) protein (e.g.,
AcrB), which is located in the inner (cytoplasmic)
membrane; a periplasmic accessory protein (also
known as a membrane fusion protein - MFP) (e.g.,
AcrA); and an outer membrane protein channel (OMP)
(e.g., TolC) [51], which is located in the outer mem-
branes of Gram-negative bacteria [28,51,126,142].
Many RND-type systems were described in Gram-
negative bacteria, amongst which multidrug-resistant
clinical pathogens constitute particularly a problemat-
ic group. Occurrence of the RND antibiotic trans-
porters in a chosen nosocomial pathogens presents
table 1. In some species, for example Pseudomonas
aeruginosa, there are a few systems described which
can be active at the same time. Clinical isolates of
Pseudomonas aeruginosa can express (overexpress)
two efflux pumps simultaneously MexAB-OprM and
MexXY [66] or MexAB-OprM and MexEF-OprN
[102].
In Acinetobacter baumannii AdeB is the multidrug
transporter protein, AdeA is the MFP and AdeC is the
OMP [73]. The efflux transporter (AdeB) captures its
substrates either from within the phospholipid bilayer
of the inner membrane or the cytoplasm [4] and then
transport them into the extracellular medium via OMP
(AdeC) [28]. The periplasmatic protein AdeA mediates
in the cooperation between AdeB and AdeC compo-
nents. Drug transport by different pumps families is
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driven by the transmembrane electrochemical gradient
of protons. Members of the RND family are proton
antiporters, using the proton gradient to power efflux,
exchanging one H+ ion for one drug molecule [28,91].
Figure 1 demonstrate the scheme of the structure of the
AdeABC. This system was shown to be responsible
for decreased susceptibility to a broad spectrum of
antimicrobials. Aminoglicosides, tetracyclines, eryth-
romycin, chloramphenicol, trimethoprim, fluoro-
quinolones, some β-lactams, ethidium bromide
[30,37,73,135], and also recently tigecycline [92,110],
were found to be substrates for AdeABC, although
netilmicin and gentamicin appeared to be the best one
for the pump [73].
The secondary structure of RND-type efflux pro-
teins was proposed to consist of 12 transmembrane
segments (TMS), with two long loops between TMS 1
and 2 and TMS 7 and 8 [111,126]. The trimeric form
of the OMP generates a continous, solvent-accessible
channel-like structure that spans both the outer mem-
brane and the periplasmic space [52,73,141]. MFP
could be involved in either the bringing of the inner
and outer membranes closer or the stabilization of the
OMP structure [73,84,142].
The efflux pump system AdeABC, member of
RND family, was identified in a multidrug-resistant
Acinetobacter baumannii strain in 2001 [73]. This
transporter is the main efflux system in Acinetobacter
baumannii. A lot of pumps from this family are wide-
spread amongst Gram-negative bacteria and are asso-
ciated with multidrug resistance to antibiotics in
important pathogens.
Genetic organization – regulation, expression
and overexpression
Genes of AdeABC system and function
The genes that encode AdeABC efflux pump are locat-
ed on the bacterial chromosome [75]. Typically, the
genes are organized as an operon – the structural genes
adeA, adeB and adeC are contiguous and directly ori-
ented. The gene encoding the periplasmic accessory
protein is located adjacent to the gene encoding trans-
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Table 1. RND family efflux pumps caused multidrug resistance in important clinical Gram-negative pathogens
AG – aminoglycosides, BL – β-lactams, CM – chloramphenicol, CP – cephalosporins, EM – erythromycin, FQ – fluoroquinolones, FU – fusidic acid, ML
– macrolides, NO – novobiocin, RF – rifampicin, TC – tetracycline, TM – trimethoprim, ? – unknown
porter protein, which is located adjacent to the OMP.
There are two regulatory genes, adeS and adeR,
which products are closely related to proteins of two-
component regulatory system. These genes, that are
transcribed in the opposite direction and are localized
upstream from adeA (Fig. 2). Two-component system
are signal transduction pathways in bacteria that
respond to environmental conditions (pump is
dependent on substrate) [50,73,75]. The protein
AdeR (regulator) consisted of 228 amino acids is typ-
ical transcriptional regulator and protein AdeS (sen-
sor kinase) is shorter and demonstrate activity of bac-
terial histidine kinase, that work together to regulate
target gene expression in response to stimuli. The
sensor protein monitors the environmental conditions
and activates or inactivates the response regulator
protein which controls the expression of the efflux
pump [73,75].
The sensor kinase autophosphorylates at an internal
histidine (the H box) in response to stimulus and that
the phosphate group is then transferred to an aspartate
residue of the response regulator. Phosphorilation of
each domain and the transfer of phosphoryl groups
between these domains is reversible by the phos-
phatase activity of the sensor. The histidine kinases
leads to a switch between phosphorylation and
dephosphorylation activities and modulates the active
state of the regulators, which controls structural genes
expression [9,50,138].
Experiments performed by Marchand et al. [75]
suggests, that the adeS gene appears to be essential for
expression of the adeABC operon. To asses the role of
adeRS, the adeR and adeS genes of Acinetobacter bau-
mannii BM4454 were disrupted by insertion of a sui-
cide plasmid following homologous recombination.
Inactivation of these genes restored the sensitivity to
aminoglycosides and to other substrates for the pump
in resulting mutants [75]. In addition, another experi-
ment indicates that expression of the AdeABC pump is
under the control of the RS two component system.
Spontaneous gentamicin-resistant mutants were
obtained in vitro from susceptible Acinetobacter bau-
mannii strain. Sequence analysis of their adeRS oper-
ons showed two mutations. The first one
(Thr153→Met) was located in the kinase and the sec-
ond mutation (Pro116→Leu) was located in the
response regulator; these led to constitutive expression
of the pump and MDR [75].
Inactivation of structural genes, especially adeB
encoding the protein of main transporter have also
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Fig. 1. Multidrug resistance RND efflux pump. Amg – aminoglycosides, Flu – fluoroquinolones, Tet – tetracyclines, Clo – chloram-
phenicol, Ery – erythromycin, Tri – trimethoprim, EthBr – ethidium bromide, Tge – tigecycline.
Fig. 2. Schematic organization of the ade gene cluster (adapted from [73]); 1443, 9208 cluster localization.
been describe. The derivative recombinant demon-
strated 4 to more 32 times lower MICs of antibiotics,
which are substrates of the pump than the parental
strain [73]. In contrast, examination of the contribution
of the adeC gene to multidrug resistance, showed that
mutants still had been multidrug resistant and the
AdeC protein was not essential. That AdeC is not rec-
quired for resistance suggests that AdeAB can utilize
another outer membrane constituent. The AdeK OMP
associated with the AdeIJK RND efflux pump could be
candidate [75]. Some efflux gene clusters RND pro-
teins do not encode an outer membrane protein
[3,71,79], but can mobilize other outer membrane
channels for creating a functional three-component
pumps [31,52,121,142]. 
The genetic organizations of the genes encoding
these efflux systems are also similar among different
species. However, the genes encoded RND efflux
pumps are mainly located on the chromosome, they
are detected with the different frequency [19,41,82].
The gene of the main AdeB transporter was detected
by Chu et al. [19] with the frequency of the 70%
whether the 87% through Nemec et al. [82]. All both
structural and two-component regulatory system genes
were stated about 40% of examined strains, in the
remaining cases all sorts combinations of the presence
of these genes were being watched [82].
In the RND family in Acinetobacter spp. other
pumps are also being enumerated such as AdeDE,
AdeIJK and AdeXYZ [19,30,75]. The adeB sequence
was not detected in any of the other then Acinetobac-
ter baumannii genomic DNA groups, suggesting that
adeB is an active efflux system specific to Acinetobac-
ter baumannii. The adeB gene is present exclusively in
Acinetobacter baumannii, whereas adeE and adeY are
present most frequently in Acinetobacter lwoffii [19].
Efflux pump AdeIJK has been identified in Acineto-
bacter baumannii and its characterization is under
process [75].
The AdeDE has only the membrane fusion protein
(MFP) gene adeD and the RND transporter gene adeE
clustered together. The outer membrane protein
(OMP) for AdeDE has not been identified. AdeABC
differs from AdeDE by protecting the host from cefo-
taxime, whilst AdeDE increases the host resistance to
ceftazidime and rifampicin [17,73].
Structural proteins within the RND family demon-
strate the identity in the different degree to AdeA,
AdeB and AdeC proteins. The highest identity of main
transporters was demonstrated amongst AdeB and
MexD proteins (53%); relatively high identity had
AdeZ to AdeC (67%) (tab. 2) [19,73,96]. Also a poly-
morphism of the amino acidic sequence of  the AdeB
protein is being described (11 sequential types) [42].
Local and global regulation of RND pump gene
expression
The regulators involved in efflux gene expression are
either local or global regulators. The-best studied
example of both local and global cooperation is
AcrAB-TolC system of Escherichia coli. Most RND
MDR efflux pump genes are encoded by operons that
are under the control of the local repressor genes (tran-
scriptional repressor); e.g. in Escherichia coli acrR
[87], which regulates negatively the transcription of
the acrAB operon encoding AcrAB-TolC system [69].
Other regulators demonstrate the activity of positive
activators of the transcription process, but their parti-
cipation in regulation of this type pumps is rare.
Higher described adeR is an example activator which
is a member of two-component system regulating the
adeABC expression operon in Acinetobacter bauman-
nii [47,73,75].
Expression of various efflux pumps is also con-
trolled by different global regulators. The transcription
of acrAB is primarily mediated by global regulatory
pathways such as the marRAB operon, soxRS operon
and rob, and that a major function of AcrR is that of a
specific secondary modulator [69]. The acrAB operon
and tolC are positively regulated by several transcrip-
tional activators – MarA, SoxS and Rob. The levels of
MarA and SoxS are themselves regulated by the
repressor MarR and SoxR, respectively. The activity of
Rob is modulated by metabolites, such as bile salts and
fatty acids [59]. In addition, MarA and SoxS also con-
trol micF, an antisense RNA, that down-regulate the
expression of OmpF channel protein (porin) that is
responsible for influx some antimicrobial agents
[24,87].
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Table 2. Levels of identity between proteins from RND-type
efflux systems
Level of expression
Two-component regulation systems normally mediate
the adaptive responses of bacterial cell to a broad
range of environmental stimuli [9,50,75,138]. This
system is associated with different pumps of RND
family appearing in Gram-negative bacteria [8,25,60,
81,86,94], among others AdeABC of Acinetobacter
baumannii. Level of the expression of the pump, regu-
lated by such a system, is dependent on the presence of
the stimulus (substrate) in environment of the cell,
which activating the pump for removing substrate out-
side the cell. Antibiotics can serve as inducers and reg-
ulate the expression of some efflux pumps at the level
of gene transcription or mRNA translation, by inter-
acting with regulator systems [108]. This type of
expression is named as inductive.
Some pumps are independent of environmental
stimuli and permanently active on the defined level.
Such an activity is being described as constitutive. A
recent study has demonstrated that the assembly of the
AcrA, AcrB and TolC proteins into a functional
AcrAB-TolC pump (member of RND family pumps) is
constitutive [123], occurring in the presence or
absence of substrate molecules. The AdeABC pump of
Acinetobacter baumannii can change the expression
from inductive to the high level of the constitutive
type, including the activity of the pump on the very
high level called as overexpression. It is possible in the
result of various mutations or inactivation by insertion
sequences in the local regulatory genes, including the
activator adeR in Acinetobacter baumannii [73,75]. In
other bacteria, which genes encoding pumps are regu-
lated by repressors also could be derepressed by muta-
tions in this genes [1,112]. These changes lead to mul-
tiple antibiotic resistance of bacteria.
Spontaneous gentamicin-resistance, which is asso-
ciated with single point mutations in adeR
(Pro116→Leu) and adeS (Thr153→Met) are known to
cause AdeABC constitutive overexpression of the
efflux pump and MDR in Acinetobacter baumannii
[73,75]. Up-regulation the transporter AdeB can
accompany mutations on different genes conditioning
resistance to the given antibiotic. Higgins et al. [37]
found a 20-fold increase in mRNA transcript of the
adeB gene from two outbreak strains of Acinetobacter
baumannii, which were clones of the pretherapy strain
obtained earlier in the outbreak. It was parallel with
mutations in gyrA and parC gene encoding DNA
gyrase and topoisomerase IV, respectively. Acineto-
bacter baumannii has been shown to mutate rapidly in
gyrA and parC under the selective pressure of fluoro-
quinolones in vivo and at the same time to up-regu-
late the efflux pump AdeB. Ciprofloxacin pressure
was responsible for the selection of the efflux pheno-
type in addition to the topoisomerase mutations.
Importantly, these data illustrate the propensity for
Acinetobacter baumannii to develop multi-drug resist-
ance rapidly [37].
The newest examinations show the participation of
the AdeABC efflux pump in the resistance to newer
antibiotics in Acinetobacter. Experiment performed by
Ruzin et al. [110] suggests, that AdeABC MDR efflux
pump decreased susceptibility to tigecycline – the first
member of a new class of modified tetracycline
antimicrobials known as glycylcyclines. In this study
the adeB gene was disrupted by insertional inactiva-
tion using a suicide plasmid in two derivative mutants
constructed from two clinical isolates. Insertional inac-
tivation of the adeB gene resulted in a decrease in the
MICs of tigecycline and other antimicrobials. In addi-
tion, analyses of the adeRS locus were performed to
determine the reason for constitutive overexpression
of adeABC in two parental clinical strains. The adeS
gene was disrupted by an insertion sequence ISABA-I,
whereas it remained intact in tigecycline-susceptible
strains [110]. ISABA-I element was previously identi-
fied in Acinetobacter spp. and is though to affect the
expression of antibiotic resistance genes that are adja-
cent to the site of insertion [114]. 
The results received by Peleg et al. [92] can also
indicate that efflux mechanism play a role in reduced
tigecycline susceptibility in Acinetobacter. In two
strains they found multiple point mutations in adeR
and adeS genes, which may lead to pump overexpres-
sion. They also put forward a hypothesis, that
increased expression of adeB is associated with
increased MICs of tigecycline. They compared parent
strain with isogenic derivative strain, which was in
vitro exposed to tigecycline. A 12-fold increase in MIC
tigecycline and a 25-fold increase in adeB expression
was observed, however, the lack of mutations in this
strain compared to its isogenic parent strain, indicates
that other mechanisms for increased pump activity are
also involved. The MICs for other antimicrobials were
also increased. The tigecycline MIC was reduced to
the level of the parent strain using PAβN as inhibitor
various pumps. The MICs for other antimicrobials
were also reduced. These results strongly support, that
participation of the MDR pumps in the resistance to
tigecycline is evident, as well as tigecycline exposure
may increase the activities of many pumps.
Natural functions of RND efflux pumps
The natural functions of the different RND pumps are
still a topic of debate. The physiological role of these
systems is evasion of such naturally produced mole-
cules, thereby allowing the bacterium to survive in its
ecological niche. Natural functions suggested for
efflux pumps include: removal of metabolic products
(e.g., fermentation end products and toxins), removal
of toxins, buffering the organisms against surges in
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pools of potentially toxic metabolites [36]. It has been
suggested that the natural function of RND pumps
might also include efflux of signal molecules required
for cell-to-cell signaling (quorum sensing) [103].
Pseudomonas aeruginosa secretes a quinolone, desig-
nated PQS (Pseudomonas quinolone signal), which
acts as quorum-sensing signal [95] and overexpression
of MexEF-OprN was shown to affect PQS signalling
[49]. This is a very interesting finding as quinolones
constitute a widely used group of antimicrobials and
are substrates for RND pumps. 
It has also been shown in tissue culture studies that
components of RND efflux pumps are important in the
invasion, adherence, and/or colonization of the host
cell. Decreased cellular invasion was observed with
mutant Pseudomonas aeruginosa PAO1 with inacti-
vated mexB [38].
The AcrAB pump of Escherichia coli was found to
have the highest affinity for bile salts. The natural
habitat of Escherichia coli is the enteric tract and
efflux is a protective mechanism [14,55,83,101,122].
Other functions of this pump are participation in
adherence, colonization and invasion of host cells
[14]. AcrAB-TolC also could play a role in the trans-
port of the calcium-channel components in the
Escherichia coli membrane [46], might export hor-
mones [26].
Efflux pump inhibitors
The importance of efflux as a mechanism of resistance
to a variety of antimicrobial agents makes developing
efflux inhibitors an attractive strategy, especially in the
case of a broad spectrum pumps of multidrug resist-
ance bacteria such as Pseudomonas or Acinetobacter.
Inhibition of these pumps may be achieved at different
levels: by inhibiting drug binding to the inner mem-
brane pumps, by inhibiting the interactions of different
components of a multi-component pump, by targeting
the energy source of pumps, or by targeting the regu-
latory networks that control the expression of efflux
pumps. A few putative bacterial efflux pump inhibitors
have been described [88,119]. 
The first broad-spectrum RND pump inhibitor,
MC-207,110 (phenylalanyl-arginyl-β-naphthylamide)
was reported to be capable of reversing the MDR phe-
notype of Pseudomonas aeruginosa and several other
Gram-negative bacteria [67,105]. It has also been test-
ed in Acinetobacter baumannii clinical isolates
[89,92,107]. Reduction in the MIC of nalidixic acid
after PAβN addition was observed, though there was
no effect in the case of ciprofloxacin [107]. Recently
study, demonstrated decrease of tigecycline MIC and
other antimicrobials, including gentamicin, to-
bramycin, chloramphenicol, and several β-lactams
after exposure to PAβN [92]. Activity of another puta-
tive efflux pump inhibitor, 1-(1-naphthylmethyl)-
piperazine (NMP), was also analysed and compared to
PAβN activity in MDR isolates of Acinetobacter bau-
mannii. PAβN at low concentration (25 mg/L) had
highly selective action on the reduction in the MIC of
rifampicin and clarithromycin. At a higher concentra-
tion (100 mg/L), NMP was more active than PAβN.
NMP can partially reverse MDR in Acinetobacter bau-
mannii and differs in its activity from that of PAβN in
this species [89].
Because human cells use efflux pumps as well, the
development of a truly broad-spectrum efflux pump
inhibitor would theoretically increase the risk of toxic-
ity. Despite these challenges, continued research into
development of inhibitors of resistance mechanisms is
clearly needed.
Conclusions
During the last 20 years Acinetobacter baumannii has
become an important opportunistic pathogen cause of
nosocomial infections with multiple outbreaks. Acine-
tobacter baumannii cause serious morbidity and mor-
tality in the immunocompromised patient, particularly
in intensive care units.
Efflux mechanisms are widespread in bacteria and
have a role in establishing the level of both suscepti-
bility and resistance to various antimicrobial agents.
Multidrug resistant Acinetobacter baumannii strains
and other bacteria determine the very considerable
therapeutic problem as a result of the activity of efflux
pumps with a broad spectrum even if AdeABC.
Recent advances in genome sequence analyses,
availability of molecular structures and a more pro-
found understanding of the function and regulation of
efflux systems will facilitate exploitation of pumps as
new drug targets. Efflux pump inhibitors would be
invaluable tools to help clear bacterial infection
because of their dual function: restoration of the activ-
ity of agents to which efflux pumps confer resistance
and reduction in the ability of bacteria to colonize their
host or even to cause infection. Identification and clin-
ical development of an effective and safe efflux-pump
inhibitors to be used in combination with existing or
new antimicrobials is particularly appealing.
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